Kades & Cheifetz LLC Purchases 35 Shares of Amgen Inc. (NASDAQ:AMGN)

Kades & Cheifetz LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 3.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,052 shares of the medical research company’s stock after buying an additional 35 shares during the period. Kades & Cheifetz LLC’s holdings in Amgen were worth $339,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Trust Co. of Toledo NA OH boosted its holdings in Amgen by 4.1% in the third quarter. Trust Co. of Toledo NA OH now owns 27,187 shares of the medical research company’s stock worth $8,760,000 after acquiring an additional 1,080 shares in the last quarter. Weybosset Research & Management LLC grew its position in Amgen by 7.7% in the 3rd quarter. Weybosset Research & Management LLC now owns 700 shares of the medical research company’s stock valued at $226,000 after purchasing an additional 50 shares during the period. Davis Capital Management increased its stake in Amgen by 0.8% during the 3rd quarter. Davis Capital Management now owns 5,840 shares of the medical research company’s stock valued at $1,882,000 after purchasing an additional 49 shares in the last quarter. Park National Corp OH raised its holdings in Amgen by 2.6% during the third quarter. Park National Corp OH now owns 2,210 shares of the medical research company’s stock worth $712,000 after buying an additional 55 shares during the last quarter. Finally, Neville Rodie & Shaw Inc. increased its position in shares of Amgen by 19.2% during the third quarter. Neville Rodie & Shaw Inc. now owns 1,430 shares of the medical research company’s stock worth $461,000 after acquiring an additional 230 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Down 0.2 %

AMGN stock opened at $319.73 on Thursday. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85. The company has a market capitalization of $171.51 billion, a price-to-earnings ratio of 45.68, a price-to-earnings-growth ratio of 2.98 and a beta of 0.61. The business’s 50 day moving average price is $327.92 and its two-hundred day moving average price is $308.56.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. During the same period in the prior year, the company earned $5.00 earnings per share. The firm’s quarterly revenue was up 20.1% compared to the same quarter last year. As a group, analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AMGN. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 price target (up previously from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Oppenheimer reiterated an “outperform” rating and issued a $380.00 price objective on shares of Amgen in a research note on Wednesday, August 7th. Royal Bank of Canada restated an “outperform” rating and issued a $362.00 price objective on shares of Amgen in a research note on Thursday, September 26th. Wells Fargo & Company cut Amgen from an “overweight” rating to an “equal weight” rating and lifted their target price for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. Finally, Morgan Stanley reduced their price target on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research report on Thursday, July 11th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $325.55.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.